Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
?
12 out of a million need thus if successful.
8 billion / 1 million is 8,000 x 12 = 96,000x 70% = 672,000 least number of potential candidates world wide using the lowest numbers and percentages?...[from the blue print inet site previously posted today.)
Absolutely. IMO, this candidate although in phase 2 human trials, was third on my list of value/potential in pipeline. OSA program has significant potential while KRM-II-81 has had a multitude of preclinical success and with deep progress in NIH trials could be a life changer: for investors, more importantly for patients!
I don't know! But I am sure glad I got some of this one! We are headed not to Copper, but skip right to Silver my Friend!!!
“RespireRx Pharmaceuticals Inc. has announced a major development in the research and development of treatments for spinal cord injury (SCI). The Department of Defense (DOD) has approved a $1.8 million research grant to fund a Phase 2A and 2B clinical study to test the safety and efficacy of CX1739, RespireRx’s lead clinical AMPAkine, in improving bladder function and motor activity in individuals with SCI.
The grant has been awarded to Shirley Ryan AbilityLab, a renowned rehabilitation research hospital in Chicago. The study will be conducted under the leadership of Dr. Milap Sandhu, a research scientist at Shirley Ryan AbilityLab, in collaboration with Dr. Arnold Lippa from RespireRx and Dr. David Fuller from the University of Florida.”
https://bitperfect.pe/en/groundbreaking-research-aims-to-improve-bladder-function-in-individuals-with-spinal-cord-injury/
Wow! This wasnt even on my near term radar based off last PR!
Again, how in the world was this stock trading so low market cap considering all the potential in their pipeline??
“the Department of Defense (DOD) has approved a $1.8 million translational research award to Shirley Ryan AbilityLab to fund a two stage Phase 2A and 2B clinical study in order to determine the safety and efficacy of CX1739, its lead clinical AMPAkine, to improve bladder function and motor activity in individuals with spinal cord injury (SCI).”
https://www.globenewswire.com/news-release/2024/05/29/2889855/0/en/RespireRx-Pharmaceuticals-Inc-Announces-a-Department-of-Defense-Award-to-Fund-a-Phase-2-Clinical-Study-to-Determine-the-Safety-and-Efficacy-of-CX1739-its-Lead-AMPAkine-to-Improve-B.html
Holy Fuck!!! This is Big News!!!!
Compared to their sleep apnea and non-opiode drugs, this Sci drug helps the least percentages/numbers but, if one of rspi drugs such as this GETS $1.8 million to carry it through phase 2a and 2b of HUMAN clinical and at the #1 medical facility as so named, THEN one can expect the praise given to the other 2 above mentioned drugs the DR.s involved at RSPI have given to them, to have even more gravitas going forward as this is real stuff?
One of you guys sell your house and buy this co!
This is due for another pump.. it usually gets here and then another pump cycle starts
Some shares getting soaked up here!
don't push too hard or uncle Jeff with RS this thing!!
looks like we need a pump to clear .0008. I will do my part soon.
Darn the character set in this site.
Market research in Japanese:
???????????:?????????2032??????
By Khangan Millind
5? 24, 2024
“????????????????????????(ADHD)???2022??161?3,000??????????????????????7.1%?????2032????321?4,000???????????????????”
“Polaris Market Research? ??? ???????????2024?:??????????????????????2032?????????????????????????????????????????? “
“????????????????????????????
???? ????????? LP
????????????????LLC?
???·???????????
?????·??????(???????)????????
??????????
???????·???·?????
GSK????
?????·???·?????·????????
????????????????
??????AG
??????????
????????
????? ???? LP
RespireRx ????????????????
????????????
??????????
???????????”
https://www.lecotox.net/%E6%B3%A8%E6%84%8F%E6%AC%A0%E9%99%A5%E5%A4%9A%E5%8B%95%E6%80%A7%E9%9A%9C%E5%AE%B3%E5%B8%82%E5%A0%B4%EF%BC%9A%E5%8C%85%E6%8B%AC%E7%9A%84%E3%81%AA%E6%A5%AD%E7%95%8C%E6%A6%82%E8%A6%81%E3%81%A82032/
RSPI tons of potential for sure
Then nickels and dimes!!!
Even if they max out the authorized shares at 2 billion to cover warrants and debt conversions, 10 pennies would be a 200 million market cap. More than plausible if KRM-II-81 is as advertised and BP strike a deal.... I would hope they can keep the OS share count much much lower as well..
RSPI I just keep thinking to myself. BRING ON THE PENNIES. LOLOL
If you have invested in other OTC stocks for any period of time, you learn quickly there is just tons of roadblocks to success, especially when loan sharks are primary source of funding. Pharma business is a bit more legit then most other OTC ideas/stocks, yet because the potential is so enormous on the pharma side, it can be ripe for all kinds of disputes and arguments between stakeholders. Hopefully that is not the source of the silence.
Reality here is the stock trades well less than a million in valuation, how it got so low is beyond me. The market valuation potential is in the 100s of millions short term if either BP gets involved with KRM-II-81 or the OSA work moves into human trials. Longer term many multiples of that and of course the most recent storied pharma OTC stocks of years past went wild in valuation on much much less potential.
Always feels like market forces drag high potential stocks through the bottom mud before becoming a shining star. Fingers crossed and good luck to all.
The sense I get from DD on the epilepsy path, is that there is likely enough preclinical success and foundation to begin human trials for the epilepsy medical indications. How this same drug KRM-II-81 melds with utilization for the pain/opioid mitigation path and who/how might BP be interested is I am guessing waiting on final NIH preclinicals, presumably in progress, but no timetable from the company.
Similar thought here. The lack of SEC reporting considering past diligence to such, BOD loan and promising progress is illogical.
Quiet before the storm is what I feel too…
Revolutionary KRM-II-81: A New Hope for Drug-Resistant Epilepsy Patients
https://www.neurexplain.com/2024/01/18/revolutionary-krm-ii-81-a-new-hope-for-drug-resistant-epilepsy-patients-2/
Bullishness says one buyer last Friday at a million and another 1.48 million.
I think thus is quiet before there finding a guardian from predation...like an Elon Musk...heck he bought Twitter!
Surely in all the world over, just for the sake of a nonopiode coming to market, all persons known have been asked to help at least get this nonopiode funded to completion of sufficient efficacy or not.
There h as to have been and an ongoing campaign among uncorrupted medical and scientific and business and monied people.
$1billion/ 100,000 newbies = $10,000 each.
But $100 million funded by 100,000 newbies for the nonopiodes sake is $1,000 each.
I would donate $1,000 to a cause IF sufficient to see it through.
BOD lent $100,000. New and existing talent took remuneration in stock.
Who gambles pay and future benefits just recently, like the new VP guy with BP ties and experience only to be vanquished 6 months later by no funding.
I think good news soon...phoney on timely reporting, especially if bona fides for a reasonable extention exist....NIH needs to pony up those bona fides!!!!!
Well, I guess it can go bust andBP pick its research up for a song...or a group of BP to minimize impact on opcode sales if the nonopiode replaced them.
They have hidden patents for all sorts of things according to some...
You would think Musk would buy it for a billion just to keep the research progressing without predation...
Yes agree. What scares me most is the silence. I started investing in this company 4/2021. Been buying ever since Have not sold one share. The current status of this company is questionable IMO. No news is not good.
Well, one perspective is that the primary reasons companies are in the public markets is to raise funds for developing the company and reward/incentivize insiders and executives to garner success.
Considering past filings have indicated people getting paid and warrant pricing at .0015 and then the silence and lack of SEC filings severely inhibits raising funds, etc..... Narrows the possibilities of paths going forward.
why buy now, just wait till it gets to .0003 then buy. they have diluted, now all we need is a RS to confirm the big middle finger to Shareholder Value. so sick of shady companies
I'd this were a dog, why would over 23 million be purchased, a high volume?
Gotta be knowers buying from people who have to sell off to make ends meet or are fed up?
Agreed. Shares are being scooped up though. Often see these takedowns right before launch, but who knows. Silence reigns.
This can only realistically be a n intermediate to long term play?
For instance if you bought at 1 cent a share, came back Jan. 1st 2025 and sp was 2 cents, you doubled your value...100x gain. If each year thereafter with slow progress the sp rose 1 cent, then each year you gain 100% of initial investment, and pay no taxes on its accumulation of gains if you don't sell.
Crazy easy not-short-term-investment or easy to drive you crazy...whatever one makes of it?
Little weird not a single trade today
Good question.
CEO stated in interview these tier 3 preclinicals was "intermediate" type work; short term wanting to open "purse strings." Over 3 months ago now they issued the report on KRM-II-81, one would think some progress in last stage would be in the cards. The publications of all previous preclinical work related to KRM-II-81 appear to be pointing towards at minimum some level of human trials for some indications. No expert, but maybe these tier 3 preclinicals will help decide how many or which paths to go forward with into human trials for the various types of pain/epilepsy indications?
Is there a time certain by which we will know whether this company can qualify to enter human trials or fails to qualify for human trials?
Yes i agree the pain/epilepsy candidate is the real big time asset that can potentially bring significant BP dealings.
The govt. Can print money. If NIH does not become FUNDER OF LADT RESORT, then corporate shenanigans within Bo is colluding to keep thus actively going forward but in dire straights, so CHEAP, or to put the kibosh on it from happening so as to not interfere with massive opioid based drugs they are making profits from...the NIH effort is insincere window dressing if forward progress is squelched and even nixed due to lack of essential resources.
Yeah, would love to hear an update as to progress on their OSA program/plans. Have preclinicals with new formulations been going on or successful to set up a phase 3 human trial? There is 0 valuation for the OSA program shown in the current market cap of RSPI.
IMO however, the pain/epilepsy candidate is the real big time asset that can potentially bring significant BP dealings.
I dont think ever missing SEC filings is a good sign especially in light that they have historically been diligent with updating shareholders. However, if you read their filings they acknowledge this from last 10-Q:
"At present, we believe that we are hindered primarily by our public corporate structure, our OTC Pink Market listing and our low market capitalization as a result of our low stock price as well as the weakness of our balance sheet."
"We believe that some or all of our assets should be licensed, sub-licensed, joint ventured or even sold and have initiated efforts to do so"
I believe any serious partnership or money infusion will come with a requirement to move away from OTC shenanigans. They already have taken steps to do so with the OSA program in Australia. A BOD member loaned them 100k with only warrants backing it up and the CEO has significant loans and investments provided as well. IMO the direction of the story is being foretold although far from certain.
ResolutionRx
https://www.primarymarkets.com/capital-raising-company/resolutionrx/
Funding $3.1 mill
https://sleepreviewmag.com/sleep-disorders/breathing-disorders/obstructive-sleep-apnea/resolutionrx-secures-3-1m-sleep-apnea-drug-clinical-trial-rd/
SEC filing
https://www.sec.gov/Archives/edgar/data/849636/000149315223018786/ex99-2.htm
LinkedIn
https://www.linkedin.com/company/resolutionrx-ltd
Website
https://www.resolutionrx.com.au/
Info on primary markets
https://www.investmentmarkets.com.au/listings/resolutionrx-primarymarkets-pty-ltd-663adf2fb547a60012e504e2
Contract
https://contracts.justia.com/companies/respirerx-pharmaceuticals-inc-7385/contract/1248882/
Yes they have been pretty good about filings and now nothing for 10-k, 10-q currently, strange maybe a good sign that they are working behind the scenes currently . GLTA
That is what I am most curious to hear about is the NIH tier 3 preclinical progress. I think it is a pretty big deal and will decide the fate of when/if this company moves forward on the other development programs. My opinion is it could prove their pain/epilepsy candidate to be extremely valuable leading to a big BP deal and NIH grant funding or just somewhat valuable or not valuable at all, although I think there has been enough success to indicate some value along some paths. Maybe too this is why not bothering with 10-k, 10-q currently?
No idea how long those trials take. What I could find implied maybe a few months for the animal testing part, but who knows what prep, post and follow-up work is included. I am long for the boom or bust of it all. Judging by the filings, so are most of the insiders, institutional investor types associated. Could be many moons away before we hear anything or really could be anytime too. Patiently waiting.
All of the above would be nice or 2 of the 4 , 1 of the 4 anything would be nice . Would like to hear an update on NIH funding maybe and the stage 3 progression.
Agreed!
Prepare to lose and hope to be enormously successful. For me the risk v. reward ratio continues to be tremendous for speculative money. Good Luck to all...
Patience !
You mean like a 10-k or 10-q that are missing and overdue? Or maybe an update on the OSA program and new formulations, presumably in preclinicals?
Or a shareholder update as to approach with NIH, potential milestones and paths forward? Does seem rather odd, all things considered.....
While certainly there is a ton of risk as these OTC equities deal with a ton of ridiculous issues that can be hugely negative for investors.... I optimistically look at a few of the key happenings past 6 months and piece together what "could be". They hired a VP last December who basically sounds like a closer/deal maker and has equity incentive to push across the goal line. Then the continued success stories and publications concerning KRM-II-81 progressing positively with many possible paths to develop for multiple medical indications that need better treatment options. The last real communication was the CEO interview in March. In a nutshell, that interview seemed genuinely confident in completing the NIH preclinicals while hoping to open investment "pursestrings". My guess is this is where they are at. Awaiting to see if the NIH trials prove their candidate drug to be "somewhat" valuable, "extremely" valuable or not that valuable at all. This determination probably sets the course for all other future endeavors.
Someone is correct in suggesting it is all a gamble. Pharma business is a gamble. All OTC investing is a gamble. Prepare to lose and hope to be enormously successful. For me the risk v. reward ratio continues to be tremendous for speculative money. Good Luck to all...
Followers
|
344
|
Posters
|
|
Posts (Today)
|
4
|
Posts (Total)
|
48486
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators oldstocks DTGoody powerbattles fly_fisherman archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
---|---|---|---|
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
8-K | 10/02/2023 | 09/26/2023 | PDFRTFHTMLXLS |
10-Q | 08/21/2023 | 06/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 08/14/2023 | 06/30/2023 | PDFRTFHTML |
8-K | 08/09/2023 | 08/03/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |